Skip to main content
NewslettersWatchlist

Haemonetics Corp(HAE-N)
NYSE

Today's Change
Real-Time Last Update Last Sale Cboe BZX Real-Time
Day Low82.89
Day High85.29
Open:84.75
Price movement based on the high, low and last over the given period.
Previous Close
52-Week High/Low
Volume
Average Volume
Price/Earnings (TTM)
Forward Annual Dividend & Yield
Market Capitalization, $M
5-Day Change
Realtime quote and/or trade prices are not sourced from all markets.
Select a category then submit the form to load news
Newswire.ca
HAEMONETICS COMPLETES ACQUISITION OF OPSENS
Baystreet
Stocks in play: OpSens Inc.
Newswire.ca
OPSENS RECEIVES FINAL ORDER FOR ARRANGEMENT WITH HAEMONETICS
Newswire.ca
OPSENS' SHAREHOLDERS APPROVE ARRANGEMENT WITH HAEMONETICS
Newswire.ca
OPSENS OBTAINS REGULATORY CLEARANCE OF ARRANGEMENT IN THE UNITED STATES AND CANADA; REGULATORY APPROVALS CONDITION SATISFIED
Newswire.ca
INDEPENDENT PROXY ADVISORY FIRM ISS RECOMMENDS SHAREHOLDERS VOTE "FOR" OPSENS INC. PLAN OF ARRANGEMENT WITH HAEMONETICS CORPORATION
Newswire.ca
OPSENS RECEIVES INTERIM ORDER AND FILES MANAGEMENT INFORMATION CIRCULAR IN CONNECTION WITH SPECIAL MEETING OF SHAREHOLDERS
Newswire.ca
OPSENS SIGNS DEFINITIVE AGREEMENT FOR ITS ACQUISITION BY HAEMONETICS
PR Newswire
Haemonetics Sets Date for Publishing Second Quarter Fiscal Year 2024 Results: November 2, 2023
PR Newswire
Haemonetics Announces European Expansion for VASCADE® Vascular Closure System
PR Newswire
Haemonetics 1st Quarter Fiscal Year 2024 Earnings Release Available on Investor Relations Website
PR Newswire
Diane M. Bryant Joins Haemonetics' Board of Directors
PR Newswire
Haemonetics Sets Date for Publishing First Quarter Fiscal Year 2024 Results: August 8, 2023
PR Newswire
Haemonetics Receives FDA Clearance for Enhancements to NexSys PCS® Plasma Collection System
PR Newswire
Haemonetics 4th Quarter Fiscal Year 2023 Earnings Release Available on Investor Relations Website
PR Newswire
Haemonetics Sets Date for Publishing Fourth Quarter and Fiscal Year 2023 Results: May 11, 2023
PR Newswire
Haemonetics Publishes Inaugural Corporate Responsibility Report
Business Wire
Vivasure Medical Announces FDA IDE Approval to Initiate U.S. Pivotal Study
PR Newswire
Haemonetics Introduces Next Generation "Intelligent Control" Software for Cell Saver® Elite®+ Autotransfusion System
PR Newswire
Haemonetics to Present at Raymond James 44th Annual Institutional Investors Conference
PR Newswire
Haemonetics 3rd Quarter Fiscal Year 2023 Earnings Release Available on Investor Relations Website
PR Newswire
Haemonetics Sets Date for Publishing Third Quarter Fiscal Year 2023 Results: February 7, 2023
MarketBeat
How 2022's Biggest Healthcare Gainers Could Fare In 2023
PR Newswire
Haemonetics to Present at 41st Annual J.P. Morgan Healthcare Conference
PR Newswire
Haemonetics 2nd Quarter Fiscal Year 2023 Earnings Release Available on Investor Relations Website
PR Newswire
Haemonetics Sets Date for Publishing Second Quarter Fiscal Year 2023 Results: November 7, 2022
PR Newswire
Haemonetics Appoints Roy Galvin as President, Global Plasma and Blood Center
PR Newswire
Haemonetics Earns CE Mark for VASCADE® Vascular Closure Product Portfolio
PR Newswire
Haemonetics Announces Agreement to Offer Enhanced Transfusion Management Software to Epic's Global Network of Hospitals
PR Newswire
Haemonetics to Present at the Morgan Stanley 20th Annual Global Healthcare Conference
PR Newswire
Haemonetics 1st Quarter Fiscal Year 2023 Earnings Release Available on Investor Relations Website
PR Newswire
Haemonetics Sets Date for Publishing First Quarter Fiscal Year 2023 Results: August 10, 2022

Profile

Haemonetics Corp. provides blood management solutions to customers encompassing blood and plasma collectors, hospitals and health care providers globally. Its portfolio of integrated devices, information management, and consulting services offers blood management solutions for each facet of the blood supply chain, helping better clinical outcomes. It acquired Pall Corporation's blood collection, filtration and processing product lines. It entered into a long-term supply agreement with Pall. The company acquired Hemerus Medical. It operates under 3 segments: Plasma, Blood Center, and Hospital. Plasma includes plasma collection devices and disposables, plasma donor management software, anticoagulant and saline sold to plasma customers. Blood Center includes blood collection and processing devices and disposables for red cells, platelets and whole blood as well as related donor management software. Hospital includes three product lines, namely, Hemostasis Management, Cell Salvage and Transfusion Management.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2024.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).

Copyright © 2024 Morningstar. All Rights Reserved. The information contained herein: (1) is proprietary to Morningstar and/or its content providers; (2) may not be copied or distributed; and (3) is not warranted to be accurate, complete or timely. Neither Morningstar nor its content providers are responsible for any damages or losses arising from any use of this information. Past performance is no guarantee of future results.